12月4日晚,礼来在官网发布一则新闻稿,称在SURMOUNT-5 3b期开放标签随机临床试验中,与Wegovy(Semaglutide,司美格鲁肽制剂)相比,Zepbound(Tirzepatide,替尔泊肽制剂)的相对减肥效果高出47%。 此外,在一个关键的次要终点中,使用Zepbound的人中有31.6%的人体重减轻了至少25%,而服用Wegovy的人中这一比例为16.1%。 作为目前仅有...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.